Biotech RadarJobs updated

COMPANY

Editas Medicine, Inc.

HQ: Cambridge, MA source · editasmedicine.com ↗ · New England

Clinical Phase 2

Also known as Editas Medicine · 7 open jobs · last seen Oct 23, 2026 · 7 sources

Editas Medicine is researching and developing in vivo gene editing medicines, which edit genes inside the body. From company website Source · Oct 12, 2026

Keywords: gene therapy Hemoglobinopathies Sickle Cell Disease Transfusion-dependent Beta-Thalassemia Leber Congenital Amaurosis 10 Hereditary Eye Diseases Retinal Disease Retinal Degeneration Vision Disorders Eye Disorders Congenital Thalassemia Major Thalassemia Intermedia Inherited Retinal Dystrophies Blindness Eye Diseases keratitis EDIT-301 EDIT-101

Profile checked Oct 10, 2026

7Open jobs$125.0MRaised (2 yrs)5Trials (company is sponsor)1NIH grants

Hiring

TitleLocation (from posting)Employer postedFirst seen
Associate Director, Lipid Process ChemistryCambridge, Massachusetts, United StatesOct 9, 2026Oct 12, 2026
Non-clinical Study Coordinator (Contract)Cambridge, Massachusetts, United StatesOct 7, 2026Oct 12, 2026
Senior Medical Director, Clinical DevelopmentCambridge, Massachusetts, United StatesOct 7, 2026Oct 12, 2026
Vice President, Regulatory AffairsCambridge, Massachusetts, United StatesOct 7, 2026Oct 12, 2026
Senior Specialist, Quality Systems ManagementCambridge, Massachusetts, United StatesSep 17, 2026Oct 12, 2026

See all 7 jobs

Timeline

  1. Raise Follow-on offering: $125M (total, as published), announced May 26, 2026. Source: company release on GlobeNewswire. source ↗
  2. Trial start —: A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301 source ↗
  3. Trial start Phase 1/Phase 2: EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) source ↗
  4. Trial start Phase 1/Phase 2: A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) source ↗
  5. Trial start Phase 1/Phase 2: Single Ascending Dose Study in Participants With LCA10 source ↗
  6. Trial start —: Natural History Study of CEP290-Related Retinal Degeneration source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $125.0M. Last 2 years.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT06363760A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301Not listedEnrolling by invitationJun 17, 20242040-08 (estimated)
NCT05444894EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)Phase 1/Phase 2Active, not recruitingApr 29, 20222025-09 (estimated)
NCT04853576A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)Phase 1/Phase 2Active, not recruitingMay 4, 20212025-08 (estimated)
NCT03872479Single Ascending Dose Study in Participants With LCA10Phase 1/Phase 2Unknown status (ClinicalTrials.gov)Sep 26, 2019May 23, 2025 (estimated)
NCT03396042Natural History Study of CEP290-Related Retinal DegenerationNot listedCompletedDec 17, 2017May 6, 2022 (actual)

NIH awards 1

Annual award amounts. Total $225K.

Open jobs 7

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Associate Director, Lipid Process ChemistryCambridge, Massachusetts, United StatesOct 9, 2026Oct 12, 2026Senior
Non-clinical Study Coordinator (Contract)Cambridge, Massachusetts, United StatesOct 7, 2026Oct 12, 2026Entry
Senior Medical Director, Clinical DevelopmentCambridge, Massachusetts, United StatesOct 7, 2026Oct 12, 2026Senior
Vice President, Regulatory AffairsCambridge, Massachusetts, United StatesOct 7, 2026Oct 12, 2026Executive
Senior Specialist, Quality Systems ManagementCambridge, Massachusetts, United StatesSep 17, 2026Oct 12, 2026Senior
Senior Director, Medical AffairsCambridge, Massachusetts, United StatesSep 9, 2026Oct 12, 2026Senior
Senior Director, Program Team LeadCambridge, Massachusetts, United StatesAug 24, 2026Oct 12, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Editas Medicine on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback